Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis

Carcinogenesis

Volumn 36, Issue 4, 2014, Pages 478-486

  Nakanishi, Masako ^a   Perret, Christine ^b   Meuillet, Emmanuelle J ^c   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b INSTITUT COCHIN   (France)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; VIMENTIN; DEXTRAN SULFATE; ISOMERASE; PROSTAGLANDIN E SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; COLON ULCER; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; INFLAMMATION; INTESTINE CRYPT; INTESTINE EPITHELIUM; MICROENVIRONMENT; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; ADENOMA; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; CHEMICALLY INDUCED; COLON; COLON TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; INTESTINE MUCOSA; KNOCKOUT MOUSE; MALE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DINOPROSTONE; FEMALE; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; INFLAMMATION; INTESTINAL MUCOSA; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, KNOCKOUT;

EID: 84927632162     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv004     Document Type: Article

References (53)

1. Jakobsson, P.J. et al. (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA, 96, 7220-7225.
2. Nakanishi, M. et al. (2011) Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev. Res. (Phila)., 4, 1198-1208.
3. Nakanishi, M. et al. (2013) Multifaceted roles of PGE2 in inflammation and cancer. Semin. Immunopathol., 35, 123-137.
4. Nakanishi, M. et al. (2010) mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie, 92, 660-664.
5. Fischer, S.M. et al. (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev. Res. (Phila)., 4, 1728-1735.
6. Thun, M.J. et al. (2012) The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol., 9, 259-267.
7. Arber, N. et al. (2008) Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology, 134, 1224-1237.
8. Wang, D. et al. (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29, 781-788.
9. Howe, L.R. et al. (2013) Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat., 106, 99-105.
10. Sasaki, Y. et al. (2012) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene, 31, 2943-2952.
11. Nakanishi, M. et al. (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res., 68, 3251-3259.
12. Takahashi, R. et al. (2014) Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. Biomed. Pharmacother., 68, 71-77.
13. Rosenberg, D.W. et al. (2009) Mouse models for the study of colon carcinogenesis. Carcinogenesis, 30, 183-196.
14. Feagins, L.A. et al. (2010) Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig. Dis. Sci., 55, 226-232.
15. Lewis, J.D. et al. (1999) Cancer risk in patients with inflammatory bowel disease. Gastroenterol. Clin. North Am., 28, 459-477.
16. Tanaka, T. et al. (2006) Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer, 118, 25-34.
17. Yoshimi, K. et al. (2009) Enhanced colitis-associated colon carcinogenesis in a novel Apc mutant rat. Cancer Sci., 100, 2022-2027.
18. Colnot, S. et al. (2004) Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab. Invest., 84, 1619-1630.
19. Perše, M. et al. (2012) Dextran sodium sulphate colitis mouse model: traps and tricks. J. Biomed. Biotechnol., 2012, 718617.
20. Hara, S. et al. (2010) Prostaglandin E synthases: Understanding their pathophysiological roles through mouse genetic models. Biochimie, 92, 651-659.
21. Iizuka, M. et al. (2011) Wound healing of intestinal epithelial cells. World J. Gastroenterol., 17, 2161-2171.
22. Shtutman, M. et al. (1999) The cyclin D1 gene is a target of the betacatenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA, 96, 5522-5527.
23. Rigas, B. et al. (1993) Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523.
24. Kune, G.A. et al. (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res., 48, 4399-4404.
25. Flossmann, E. et al. (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 369, 1603-1613.
26. Leshno, M. et al. (2008) Point/Counterpoint: Aspirin is clinically effective in chemoprevention of colorectal neoplasia: point. Cancer Epidemiol. Biomarkers Prev., 17, 1558-1561.
27. FitzGerald, G.A. et al. (2001) COX-2 inhibitors and the cardiovascular system. Clin. Exp. Rheumatol., 19(6 suppl. 25), S31-S36.
28. Bresalier, R.S. et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 352, 1092-1102.
29. Degousee, N. et al. (2008) Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation, 117, 1701-1710.
30. Wang, M. et al. (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA, 103, 14507-14512.
31. Wu, D. et al. (2009) Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat., 90, 21-25.
32. Cheng, Y. et al. (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest., 116, 1391-1399.
33. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
34. Aggarwal, B.B. et al. (2006) Inflammation and cancer: how hot is the link? Biochem. Pharmacol., 72, 1605-1621.
35. Canavan, C. et al. (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther., 23, 1097-1104.
36. Rutter, M. et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 126, 451-459.
37. Eaden, J.A. et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535.
38. Triantafillidis, J.K. et al. (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Devel. Ther., 5, 185-210.
39. Takeuchi, K. et al. (2010) Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J. Pharmacol. Sci., 114, 248-261.
40. Nitta, M. et al. (2002) Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand. J. Immunol., 56, 66-75.
41. Kabashima, K. et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest., 109, 883-893.
42. Hirata, I. et al. (2001) Estimation of mucosal inflammatory mediators in rat DSS-induced colitis. Possible role of PGE(2) in protection against mucosal damage. Digestion, 63 (suppl. 1), 73-80.
43. Robert, A. et al. (1979) Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology, 77, 433-443.
44. Montrose, D.C. et al. (2014) The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat., 116-117C, 26-36.
45. Taupin, D. et al. (2003) Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell Biol., 4, 721-732.
46. Yan, Y. et al. (2009) Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One, 4, e6073.
47. Manieri, N.A. et al. (2012) Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology, 143, 110-21.e10.
48. Shao, J. et al. (2006) Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res., 66, 846-855.
49. Powell, D.W. et al. (2012) Mesenchymal stem cells and prostaglandins may be critical for intestinal wound repair. Gastroenterology, 143, 19-22.
50. Barker, N. et al. (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature, 457, 608-611.
51. Al-Kharusi, M.R. et al. (2013) LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis, 34, 1150-1157.
52. Fan, Y.Y. et al. (2014) Differential effects of 2-and 3-series E-prostaglandins on in vitro expansion of Lgr5+ colonic stem cells. Carcinogenesis, 35, 606-612.
53. Qiu, W. et al. (2010) Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMACdependent apoptosis. Proc. Natl. Acad. Sci. USA, 107, 20027-20032.